OncoMatch/Clinical Trials/NCT06137144
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
Is NCT06137144 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AZD3470 for lymphoma.
Treatment: AZD3470 — This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Required: MTAP expression (central MTAP expression determination required; no threshold specified)
must provide FFPE baseline tumour tissue to meet the minimum tissue requirement for central MTAP expression determination
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: antibody-drug conjugate (Brentuximab Vedotin)
must have previously received at least 3 prior lines of therapy (including Brentuximab Vedotin and anti-PD-1 therapy) for the treatment of cHL
Must have received: anti-PD-1 therapy
must have previously received at least 3 prior lines of therapy (including Brentuximab Vedotin and anti-PD-1 therapy) for the treatment of cHL
Cannot have received: MAT2A inhibitor
Prior treatment with a MAT2A inhibitor
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 inhibitor
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
Liver function
Cardiac function
Mean resting QTcF > 470 msec or clinically important abnormalities in rhythm (ventricular arrhythmias and uncontrolled atrial fibrillation); factors that increase the risk of QTc prolongation or risk of arrhythmic events; cardiac procedures or conditions within the last 6 months: CABG, PCI or heart valve intervention vascular stent implantation, acute coronary syndrome / myocardial infarction, uncontrolled angina pectoris, use of therapeutic anti-coagulation for treatment of active thromboembolic events; severe valvular heart disease; congestive heart failure Grade II to Grade IV; prior or current cardiomyopathy; uncontrolled hypertension; brain perfusion problems such as haemorrhagic or thrombotic stroke (including transient ischemic attacks)
Adequate organ and bone marrow function. Cardiac criteria: see exclusion criteria.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Miami, Florida
- Research Site · Atlanta, Georgia
- Research Site · Boston, Massachusetts
- Research Site · Philadelphia, Pennsylvania
- Research Site · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify